Related Experiment Video
Updated: May 3, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Managing risks of TNF inhibitors: an update for the internist
Jennifer Hadam1, Elie Aoun, Kofi Clarke
1Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, PA.
Abstract:
Tumor necrosis factor (TNF) inhibitors have many beneficial effects, but they also pose infrequent but significant risks, including serious infection and malignancy. These risks can be minimized by judicious patient selection, appropriate screening, careful monitoring during treatment, and close communication between primary care physicians and subspecialists.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myocarditis IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Pericarditis III: Medical Management
Rheumatic Heart Disease IV: Nursing Management

